T1-based stratification of paramagnetic rim lesions in multiple sclerosis: Evidence of microstructural heterogeneity and clinical implications [0.03%]
基于T1的多发性硬化症参数磁盘状边缘病变分层：微结构异质性和临床意义的证据
Zhuowei Shi,Huajiao Wang,Zichun Yan et al.
Zhuowei Shi et al.
Background: Paramagnetic rim lesions (PRLs) in multiple sclerosis (MS) exhibited intrinsic heterogeneity. Objectives: We aimed to asses...
Epigenetic age and telomere length correlations in pediatric-onset multiple sclerosis [0.03%]
儿科多发性硬化症的表观遗传年龄和端粒长度的相关性研究
Jennifer H Yang,Jonathan Race,Paige Sumowski et al.
Jennifer H Yang et al.
Background: Age is the strongest factor determining disease expression in multiple sclerosis (MS). We previously demonstrated biological age acceleration in pediatric-onset MS (POMS) compared to controls with both epigene...
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial [0.03%]
奥扎莫德治疗复发型多发性硬化症的长期安全性和有效性：DAYBREAK开放标签延伸试验最终分析结果
Krzysztof W Selmaj,Lawrence Steinman,Giancarlo Comi et al.
Krzysztof W Selmaj et al.
Background: Ozanimod, a selective, oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for adults with relapsing forms of multiple sclerosis (RMS). ...
Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity [0.03%]
基于核酸免疫 Sandwich 法检测进展型多发性硬化患者的生物标志物研究
Sofia Sandgren,Aleksandra Maleska Maceski,Pascal Benkert et al.
Sofia Sandgren et al.
Background/objectives: This cohort study aimed to identify blood-based biomarkers associated with progression independent of relapse activity (PIRA) in persons with multiple sclerosis (pwMS) using the multiplex NUcleic Ac...
Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis [0.03%]
一种新型的体外诊断神经丝轻链检测方法在复发性多发性硬化症患者疾病活动预后中的临床验证
Tjalf Ziemssen,Mark S Freedman,Amit Bar-Or et al.
Tjalf Ziemssen et al.
Background: Neurofilament light chain (NfL) is a promising marker for predicting disease activity in relapsing multiple sclerosis (RMS). To date, however, there has been no commercially available NfL assay validated in MS...
Tremor and disability outcomes following deep brain stimulation for multiple sclerosis-associated tremor [0.03%]
深部脑刺激治疗多发性硬化相关性震颤的疗效及预后研究
Samantha A Banks,Matthew R Baker,Eoin P Flanagan et al.
Samantha A Banks et al.
Background: Tremor in multiple sclerosis (MS) is often refractory to medications. Deep brain stimulation (DBS) may help, but possible side effects and disease exacerbation limit its use. ...
Tiffany B Kim,Jenni Yoon Lee,Allen Brinker et al.
Tiffany B Kim et al.
Background: Immediate post-injection reactions were commonly observed in registrational trials of glatiramer acetate (GA) for the treatment of multiple sclerosis. Immediate post-injection reactions, characterized by a con...
Longitudinal modeling of upper extremity function in multiple sclerosis: Associations for clinical and sociodemographic factors [0.03%]
多发性硬化症上肢功能纵向建模：临床及人口统计学因素的相关性研究
Farren Bs Briggs,Jiayue Yang,Karlo Toljan et al.
Farren Bs Briggs et al.
Background: Upper extremity impairment is a common disabling consequence of multiple sclerosis (MS). Little is known about factors influencing upper extremity functioning in MS. ...
Psychiatric morbidity during the multiple sclerosis prodrome is associated with future disability [0.03%]
前驱期精神病态与多发性硬化症后残疾的相关性
Anibal S Chertcoff,Marta Ruiz-Algueró,Fardowsa Yusuf et al.
Anibal S Chertcoff et al.
Background: Evidence suggests a prodromal phase in multiple sclerosis (MS) identifiable via healthcare use, including psychiatric symptoms. The association between psychiatric morbidity in this phase and future outcomes r...
David E Freedman,Karen A Campbell,Anthony Feinstein
David E Freedman